Drug Trial Radar · NCT07335562
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Feb 3, 2027
Primary completion
Nov 14, 2028
Study completion Nov 11, 2030
Sponsor
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Celgene Corporation
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
Conditions
- Systemic Sclerosis
Interventions
BMS-986353Drug
Specified dose on specified days
FludarabineDrug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
TocilizumabDrug
Specified dose on specified days
RituximabDrug
Specified dose on specified days
NintedanibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The absolute change from baseline in Forced Vital Capacity (FVC) in mLTime frame: At 12 months
Locations
56 sites in 10 countries. Site status is shown where the registry gives one.
Local Institution - 0035
Scottsdale, Arizona
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Local Institution - 0069
Miami, Florida
Emory University School of Medicine
Atlanta, Georgia
Local Institution - 0139
Chicago, Illinois
Local Institution - 0084
Worcester, Massachusetts
Local Institution - 0034
Ann Arbor, Michigan
Local Institution - 0037
Rochester, Minnesota
Local Institution - 0082
Summit, New Jersey
Cleveland Clinic
Cleveland, Ohio
Local Institution - 0142
Philadelphia, Pennsylvania
Local Institution - 0143
Pittsburgh, Pennsylvania
Local Institution - 0002
Charleston, South Carolina
Local Institution - 0074
Dallas, Texas
Local Institution - 0144
Houston, Texas
Local Institution - 0008
Seattle, Washington
Local Institution - 0080
Liège, Belgium
Local Institution - 0057
Leuven, Vlaams-Brabant, Belgium
Local Institution - 0104
Halifax, Nova Scotia, Canada
Local Institution - 0088
Sherbrooke, Quebec, Canada
Local Institution - 0049
Bordeaux, France
Local Institution - 0012
Bron, France
Local Institution - 0052
Paris, France
Local Institution - 0141
Rennes, France
Local Institution - 0031
Strasbourg, Alsace, France
Local Institution - 0061
Toulouse, Haute-Garonne, France
Local Institution - 0046
Berlin, Germany
Local Institution - 0016
Cologne, Germany
Local Institution - 0028
Erlangen, Germany
Local Institution - 0042
Leipzig, Germany
Local Institution - 0032
München, Germany
Local Institution - 0033
Tübingen, Germany
Local Institution - 0038
Würzburg, Germany
Local Institution - 0106
Milan, Italy
Local Institution - 0103
Rome, Lazio, Italy
Local Institution - 0004
Milan, Milano, Italy
Local Institution - 0108
Pisa, Tuscany, Italy
Local Institution - 0123
Fukuoka, Japan
Local Institution - 0136
Maebashi, Japan
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.